课题基金 / 基金详情

A phase 2 trial to evaluate safety and immunogenicity of a next-generation COVID-19 vaccine delivered by inhaled aerosol to humans

A phase 2 trial to evaluate safety and immunogenicity of a next-generation COVID-19 vaccine delivered by inhaled aerosol to humans
一项 2 期试验，旨在评估通过吸入气雾剂向人类输送的下一代 COVID-19 疫苗的安全性和免疫原性
批准号：
466312
负责人：
Smaill Fiona M
金额：
$602.2万
依托单位：
McMaster University
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2022
资助国家：
加拿大
项目状态：
未结题
起止时间：
2022-07-01 至 2025-07-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=466312&lang=en
关键词：
Adenoviral-Vectored Antibody & T Cell Immunity Clinical Trial Covid-19 Inhaled Aerosol Mucosal Immunization Next-Generation Vaccine Respiratory Mucosal Immunity Sars-Cov2 Trained Innate Immunity

项目摘要

项目成果

Smaill Fiona M的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Despite the benefit of current COVID vaccines in preventing severe disease and death, these vaccines are relatively poor at preventing infection with new variants like Omicron and work less well in the elderly and people with weak immune systems. There is
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A phase 2 trial to evaluate safety and immunogenicity of a next-generation COVID-19 vaccine delivered by inhaled aerosol to humans
  • 批准号：
    474606
  • 项目类别：
    Operating Grants
  • 资助金额：
    $150.55万
  • 财政年份：
    2022
  • 负责人：
    Smaill Fiona M
  • 依托单位：
    McMaster University
Safety and potency of a new tuberculosis vaccine delivered by inhaled aerosol to humans
  • 批准号：
    356029
  • 项目类别：
    Operating Grants
  • 资助金额：
    $80.25万
  • 财政年份：
    2016
  • 负责人：
    Smaill Fiona M
  • 依托单位：
    McMaster University